FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2996758988> ?p ?o ?g. }

• W2996758988 endingPage "1319" @default.
• W2996758988 startingPage "1309" @default.
• W2996758988 abstract "Abstract In the near future, important translational questions of clinical relevance will be adressed by studies currently in progress. On the one hand, the role of PD-L1 expression must be further understood, after it was found to be relevant in the use of atezolizumab in first-line therapy of patients with metastatic triple-negative breast cancer (TNBC). No association between efficacy and PD-L1 expression was found in a neoadjuvant study that included pembrolizumab in TNBC. The pathological complete response rate (pCR) was higher in both patient groups with and without PD-L1 expression when pembrolizumab was added to chemotherapy. Another future question is the identification of further patient groups in which efficacy of PARP inhibitors is seen, which are licensed for the pBRCA1/2 germline mutation. These include, for example, patients with mutations in other genes, which are involved in homologous recombination, or patients with tumours that show an abnormality in global tests of homologous recombination deficiencies (HRD tests). The question of whether a PARP inhibitor can be given and with which chemotherapy combination partners is currently being investigated in both breast and ovarian cancer. While the data on improved overall survival are being consolidated for the CDK4/6 inhibitors, knowledge of molecular changes during the therapy and during progression on the therapy is growing. Both the accumulation of PI3K mutations and also PTEN changes might play a part in planning subsequent therapies. This review article summarises these recent developments in breast cancer and in part also in ovarian cancer." @default.
• W2996758988 created "2020-01-10" @default.
• W2996758988 creator A5011687402 @default.
• W2996758988 creator A5017728105 @default.
• W2996758988 creator A5021298305 @default.
• W2996758988 creator A5023008141 @default.
• W2996758988 creator A5028882183 @default.
• W2996758988 creator A5030131864 @default.
• W2996758988 creator A5042564261 @default.
• W2996758988 creator A5045891981 @default.
• W2996758988 creator A5047422350 @default.
• W2996758988 creator A5048706345 @default.
• W2996758988 creator A5053845865 @default.
• W2996758988 creator A5057393976 @default.
• W2996758988 creator A5058627245 @default.
• W2996758988 creator A5062182046 @default.
• W2996758988 creator A5071893291 @default.
• W2996758988 creator A5072762948 @default.
• W2996758988 creator A5086791040 @default.
• W2996758988 creator A5088637879 @default.
• W2996758988 creator A5089392438 @default.
• W2996758988 date "2019-12-01" @default.
• W2996758988 modified "2023-10-11" @default.
• W2996758988 title "Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy" @default.
• W2996758988 cites W1464936406 @default.
• W2996758988 cites W2000612276 @default.
• W2996758988 cites W2057366353 @default.
• W2996758988 cites W2113382133 @default.
• W2996758988 cites W2151082560 @default.
• W2996758988 cites W2167188058 @default.
• W2996758988 cites W2559679969 @default.
• W2996758988 cites W2607161983 @default.
• W2996758988 cites W2620993107 @default.
• W2996758988 cites W2621271973 @default.
• W2996758988 cites W2734897937 @default.
• W2996758988 cites W2776036154 @default.
• W2996758988 cites W2791685499 @default.
• W2996758988 cites W2801560824 @default.
• W2996758988 cites W2801956643 @default.
• W2996758988 cites W2803428420 @default.
• W2996758988 cites W2804105316 @default.
• W2996758988 cites W2805575723 @default.
• W2996758988 cites W2886477543 @default.
• W2996758988 cites W2887648164 @default.
• W2996758988 cites W2892043300 @default.
• W2996758988 cites W2896846857 @default.
• W2996758988 cites W2897422388 @default.
• W2996758988 cites W2903930049 @default.
• W2996758988 cites W2944675676 @default.
• W2996758988 cites W2945564879 @default.
• W2996758988 cites W2946550606 @default.
• W2996758988 cites W2948069739 @default.
• W2996758988 cites W2948930564 @default.
• W2996758988 cites W2969222240 @default.
• W2996758988 cites W2969231750 @default.
• W2996758988 cites W2975141952 @default.
• W2996758988 cites W2976415870 @default.
• W2996758988 cites W2980008739 @default.
• W2996758988 doi "https://doi.org/10.1055/a-1039-4458" @default.
• W2996758988 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6924326" @default.
• W2996758988 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31875860" @default.
• W2996758988 hasPublicationYear "2019" @default.
• W2996758988 type Work @default.
• W2996758988 sameAs 2996758988 @default.
• W2996758988 citedByCount "11" @default.
• W2996758988 countsByYear W29967589882020 @default.
• W2996758988 countsByYear W29967589882021 @default.
• W2996758988 countsByYear W29967589882022 @default.
• W2996758988 crossrefType "journal-article" @default.
• W2996758988 hasAuthorship W2996758988A5011687402 @default.
• W2996758988 hasAuthorship W2996758988A5017728105 @default.
• W2996758988 hasAuthorship W2996758988A5021298305 @default.
• W2996758988 hasAuthorship W2996758988A5023008141 @default.
• W2996758988 hasAuthorship W2996758988A5028882183 @default.
• W2996758988 hasAuthorship W2996758988A5030131864 @default.
• W2996758988 hasAuthorship W2996758988A5042564261 @default.
• W2996758988 hasAuthorship W2996758988A5045891981 @default.
• W2996758988 hasAuthorship W2996758988A5047422350 @default.
• W2996758988 hasAuthorship W2996758988A5048706345 @default.
• W2996758988 hasAuthorship W2996758988A5053845865 @default.
• W2996758988 hasAuthorship W2996758988A5057393976 @default.
• W2996758988 hasAuthorship W2996758988A5058627245 @default.
• W2996758988 hasAuthorship W2996758988A5062182046 @default.
• W2996758988 hasAuthorship W2996758988A5071893291 @default.
• W2996758988 hasAuthorship W2996758988A5072762948 @default.
• W2996758988 hasAuthorship W2996758988A5086791040 @default.
• W2996758988 hasAuthorship W2996758988A5088637879 @default.
• W2996758988 hasAuthorship W2996758988A5089392438 @default.
• W2996758988 hasBestOaLocation W29967589881 @default.
• W2996758988 hasConcept C102744134 @default.
• W2996758988 hasConcept C104317684 @default.
• W2996758988 hasConcept C121608353 @default.
• W2996758988 hasConcept C126322002 @default.
• W2996758988 hasConcept C143998085 @default.
• W2996758988 hasConcept C182979987 @default.
• W2996758988 hasConcept C190283241 @default.
• W2996758988 hasConcept C2776694085 @default.
• W2996758988 hasConcept C2777609662 @default.

• next